Acute Coronary Syndrome
Conditions
Brief summary
Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015, following ACS. Patient baseline characteristics will be described: (Age, Gender, Body Mass Index, Smoking status, Sociodemographic status), type of ACS and interventions, CV history and comorbidities, bleeding and respiratory history. The following outcomes will be examined: Incidence of vascular events (composite MI, Stroke, vascular death, specific vascular event and all cause death), incidence of bleeding and incidence of dysponea. Time to event for vascular events, bleeding and dyspnoea.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* First prescription (index date) for ticagrelor between Dec 2010 and Mar 2015 * At least 12 months history in database prior to first ticagrelor prescription * Linkage to Hospital Episode Statistics (HES) * Acute Coronary Syndrome (ACS) event in the three months prior to and including the index date
Exclusion criteria
Primary care prescription for clopidogrel or prasugrel between the ACS date and the index date
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to event for vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Time to event for composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Time to event for myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Time to event for all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Time to event for stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Incidence of composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Incidence of myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Incidence of all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Incidence of stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Incidence of vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Time to event for bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Time to event for dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
| Incidence of bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS) | From index date up to 12 months |
Countries
United Kingdom
Outcome results
None listed